The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549
FORM D

FORM D Estimated average burden

OMB Number: 3235-0076
Estimated average burden
hours per response: 4.00

OMB APPROVAL

Notice of Exempt Offering of Securities

1. Issuer's Identity			
CIK (Filer ID Number)	Previous	None	Entity Type
	Names		
0001645460	Imagen Bioph	narma, Inc.	X Corporation
Name of Issuer			Limited Partnership
Cue Biopharma, Inc.	vanization		Limited Liability Company
Jurisdiction of Incorporation/Org DELAWARE	janization		General Partnership
Year of Incorporation/Organizati	ion		Business Trust
X Over Five Years Ago	OH		Other (Specify)
	aif (Vaan)		_
Within Last Five Years (Spe	city rear)		
Yet to Be Formed			
2. Principal Place of Business	and Contact Information		
Name of Issuer			
Cue Biopharma, Inc.			
Street Address 1		Street Address 2	
40 GUEST STREET			
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
BOSTON	MASSACHUSETTS	02135	617-949-2680
3. Related Persons			
Last Name	First Name		Middle Name
Passeri	Daniel		R.
Street Address 1	Street Address 2		TC.
40 Guest Street	5.1.5517 (a.a.1555 <u>-</u>		
City	State/Province/Co	ountry	ZIP/PostalCode
Boston	MASSACHUSETT		02135
Relationship: X Executive Office	cer X Director Promoter		
Clarification of Response (if Nec	essary):		
Last Name	First Name		Middle Name
Suri	Anish		
Street Address 1	Street Address 2		
40 Guest Street			
City	State/Province/Co		ZIP/PostalCode
Boston	MASSACHUSETT	S	02135
Relationship: X Executive Office	cer Director Promoter		
Clarification of Response (if Nec	essary):		
Last Name	First Name		Middle Name
Millar	Kerri-Ann		
Street Address 1	Street Address 2		
40 Guest Street			
City	State/Province/Co	ountry	ZIP/PostalCode
Boston	MASSACHUSETT	S	02135
Relationship: $\boxed{\mathbf{X}}$ Executive Office	cer Director Promoter		

Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Nasshorn	Patricia	
Street Address 1	Street Address 2	
40 Guest Street		
City	State/Province/Country	ZIP/PostalCode
Boston	MASSACHUSETTS	02135
_		02133
	ector Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Pienta	Ken	
Street Address 1	Street Address 2	
40 Guest Street		
City	State/Province/Country	ZIP/PostalCode
Boston	MASSACHUSETTS	02135
Relationship: X Executive Officer Dir	ector Promoter	
Clarification of Response (if Necessary):		
Last Name	Eirat Nama	Middle Name
	First Name	
Sandercock	Colin	G.
Street Address 1	Street Address 2	
40 Guest Street		
City	State/Province/Country	ZIP/PostalCode
Boston	MASSACHUSETTS	02135
Relationship: X Executive Officer Dir	ector Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Morich	Frank	
Street Address 1	Street Address 2	
40 Guest Street		
City	State/Province/Country	ZIP/PostalCode
Boston	MASSACHUSETTS	02135
Relationship: Executive Officer X Dir	_	02100
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Driscoll	Frederick	
Street Address 1	Street Address 2	
40 Guest Street		
City	State/Province/Country	ZIP/PostalCode
Boston	MASSACHUSETTS	02135
Relationship: Executive Officer X Dir	ector Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Fletcher	Aaron	
Street Address 1	Street Address 2	
40 Guest Street		
City	State/Province/Country	ZIP/PostalCode
Boston	MASSACHUSETTS	02135
	_	
Relationship: Executive Officer X Dir	ector Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name

Howson	Tamar	
Street Address 1	Street Address 2	
40 Guest Street		
City	State/Province/Country	ZIP/PostalCode
Boston	MASSACHUSETTS	02135
Relationship: Executive Officer X Dire	ector Promoter	
Clarification of Response (if Necessary):	_	
Last Name	First Name	Middle Name
Kiener	Peter	A.
Street Address 1 40 Guest Street	Street Address 2	
City	State/Province/Country	ZIP/PostalCode
Boston	MASSACHUSETTS	02135
Relationship: Executive Officer X Dire	_	02100
Clarification of Response (if Necessary):		
4. Industry Group		
Agriculture	Health Care	Retailing
Banking & Financial Services	X Biotechnology	Restaurants
Commercial Banking	Health Insurance	
Insurance		Technology
Investing	Hospitals & Physicians	Computers
Investment Banking	Pharmaceuticals	Telecommunications
Pooled Investment Fund	Other Health Care	Other Technology
Is the issuer registered as	Manufacturing	Travel
an investment company under	Real Estate	Airlines & Airports
the Investment Company Act of 1940?	Commercial	
Yes No		Lodging & Conventions
	Construction	Tourism & Travel Services
Other Banking & Financial Service	S REITS & Finance	Other Travel
Business Services	Residential	
Energy		Other
Coal Mining	Other Real Estate	
Electric Utilities		
Energy Conservation		
Environmental Services		
Oil & Gas		
Other Energy		
5. Issuer Size		
Revenue Range OR	Aggregate Net Asset Va	alue Range
No Revenues	No Aggregate Net A	-
\$1 - \$1,000,000	\$1 - \$5,000,000	
\$1,000,001 - \$5,000,000	\$5,000,001 - \$25,00	0,000
\$5,000,001 - \$25,000,000	\$25,000,001 - \$50,0	00,000
\$25,000,001 -	\$50,000,001 - \$100,	
\$100,000,000		000,000
Over \$100,000,000	Over \$100,000,000	
X Decline to Disclose	Decline to Disclose	
Not Applicable	Not Applicable	
6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)	
Rule 504(b)(1) (not (i), (ii) or (iii))	Investment Comp	any Act Section 3(c)
	• •	

Rule 504 (b)(1)(i)	Section 3(c)(1	Section 3(c)(9)	
Rule 504 (b)(1)(ii)	Section 3(c)(2	2) Section 3(c)(10)	
Rule 504 (b)(1)(iii)	Section 3(c)(3	3) Section 3(c)(11)	
X Rule 506(b)			
Rule 506(c)	Section 3(c)(4		
Securities Act Section 4(a)(5)	Section 3(c)(5	Section 3(c)(13)	
	Section 3(c)(6	Section 3(c)(14)	
	Section 3(c)(7	7)	
7. Type of Filing			
X New Notice Date of First Sale 2022-11-16 First	st Sale Yet to Occi	ur	
Amendment			
8. Duration of Offering			
or zaradion or onormg		_	
Does the Issuer intend this offering to last more than o	one year? Yes	S X No	
9. Type(s) of Securities Offered (select all that apply	y)		
X Equity		Pooled Investment Fund Interests	
Debt		Tenant-in-Common Securities	
Option, Warrant or Other Right to Acquire Another	Security	Mineral Property Securities	
Security to be Acquired Upon Exercise of Option, V	Warrant or Other	Other (describe)	
Right to Acquire Security			
10. Business Combination Transaction			
Is this offering being made in connection with a busine merger, acquisition or exchange offer?	ess combination tr	ansaction, such as a Yes X No	
Clarification of Response (if Necessary):			
11. Minimum Investment			
Minimum investment accepted from any outside invest	tor \$0 USD		
12. Sales Compensation			
Recipient	Recip	ient CRD Number None	
Piper Sandler & Co.	665		
(Associated) Broker or Dealer X None	(Asso	ciated) Broker or Dealer CRD Number X None	
None	None		
Street Address 1	Street	Address 2	
800 Nicollet Mall			
City		Province/Country ESOTA	ZIP/Postal Code
Minneapolis State(s) of Solicitation (soloct all that apply)	_		55402
State(s) of Solicitation (select all that apply) Check "All States" or check individual States X All States	tates Fo	reign/non-US	
Recipient	Recip	ient CRD Number None	
Public Ventures, LLC	42677		
(Associated) Broker or Dealer X None	(Asso	ciated) Broker or Dealer CRD Number X None	
None	None		
Street Address 1	Street	Address 2	
4209 Meadowdale Lane	<u></u>	Provide and Oracust	710/0 / / 6 :
City Dallas	State/I	Province/Country	ZIP/Postal Code 75229
State(s) of Solicitation (select all that apply) Check "All States" or check individual States X All St	_	reign/non-US	13447
13. Offering and Sales Amounts			

Total Offering Amount \$29,999,993 USD or Indefinite
Total Amount Sold \$29,999,993 USD
Total Remaining to be Sold \$0 USD or Indefinite
Clarification of Response (if Necessary):
14. Investors
Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering. Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
15. Sales Commissions & Finder's Fees Expenses
Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions \$1,800,000 USD Estimate
Finders' Fees \$0 USD Estimate
Clarification of Response (if Necessary):
16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
\$0 USD Estimate
Clarification of Response (if Necessary):
Signature and Submission
Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below

to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- · Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Cue Biopharma, Inc.	/s/ Kerri-Ann Millar	Kerri-Ann Millar	Chief Financial Officer	2022-11-21

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

^{*} This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority